Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

And, use of over-the-counter pain relievers on day after concussion tied to faster resolution of symptoms versus five or more days after ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...

Among vaccinated people, no differences were seen in the prevalence of birth defects by brand. (HealthDay News) — COVID-19 vaccination in early pregnancy (≤20 weeks of gestation) is not associated ...

Prescribers and pharmacists are no longer expected to comply with the REMS for Tryvio. The Food and Drug Administration (FDA) has removed the risk evaluation and mitigation strategies (REMS) program ...

For centuries, women faced seemingly insurmountable barriers to entering medicine and science, and were relegated to roles as caregivers rather than ...

Eneboparatide is an investigational parathyroid hormone (PTH) receptor 1 agonist. By binding to a specific conformation of the PTH receptor 1, eneboparatide is expected to restore PTH function and ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.